Agreements

• On September 16, 2020, VectivBio, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, announced it has bolstered its development expertise with the appointment of Nader N. Youssef, M.D., as senior vice president and head of global clinical development and medical affairs.

Dr. Youssef brings more than 20 years of diverse experience in academia and the biopharmaceutical industry. Among many accomplishments, he was executive director of GI global clinical development and medical affairs for NPS Pharmaceuticals (acquired by Shire in 2015) which included responsibility for the overall regulatory and development strategy of teduglutide. During his time there, his team secured marketing approval and supported the initial launch for teduglutide in the U.S. and Europe. Dr. Youssef, most recently served as vice president of clinical development at Passage Bio and chief medical officer at Nutrinia, a biotechnology company focused on treating acute to chronic intestinal failure.